-
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Friday, August 16, 2024 - 12:25pm | 510Lykos Therapeutics has announced a strategic reorganization in response to the recent FDA decision regarding its new drug application for MDMA capsules – also known as Ecstasy or Molly – intended for treating post-traumatic stress disorder (PTSD) in adults. New Senior Medical Advisor As...